You're viewing 1 of thousands of funding rounds tracked monthly

Members receive AI-scored leads and instant alerts when companies matching their criteria raise capital. Search all rounds by stage, amount, and investor.

Carmot Therapeutics Inc. announced it raised $10.8 Million in an initial filing from an offering of $15.4 Million

08/25/17, 8:16 PM

Location

berkeley

Money raised

$10.8 million

Industry

biotechnology

Company Info

Company

Carmot Therapeutics Inc.

Location

740 heinz avenue

berkeley, california, united states

Additional Info

Carmot Therapeutics is a clinical-stage biotechnology company that is focused on the discovery and development of disease-modifying therapies for people living with metabolic diseases including obesity and diabetes. We are utilizing Chemotype Evolution, a pioneering drug discovery platform, to identify novel incretin receptor signaling targets to develop a broad pipeline of therapeutics that have the potential to produce significant weight loss and improved glycemic control. We have three clinical candidates: CT-388, CT-868 and CT-996.

Company news

Wed, 17 Jul 2024 07:00:00 GMT

Roche touts early trial success of second obesity drug candidate - Reuters

Mon, 04 Dec 2023 08:00:00 GMT

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes - Roche

Mon, 29 Jan 2024 08:00:00 GMT

Carmot Therapeutics Announces Completion of Acquisition by Roche - GlobeNewswire

Tue, 26 Jul 2022 07:00:00 GMT

Carmot Therapeutics closes $160 million Series D financing to advance clinical pipeline of novel incretin receptor modulators - Business Wire

Mon, 04 Dec 2023 08:00:00 GMT

Roche to Acquire Carmot Therapeutics for Up to $3.1B - Genetic Engineering and Biotechnology News

Mon, 24 Jun 2024 07:00:00 GMT

Top 10 smartest deals in biopharma - Fierce Biotech

Mon, 04 Dec 2023 08:00:00 GMT

Roche enters obesity market with Carmot takeover but drugs may not be available until 2030 - CNBC

Mon, 04 Dec 2023 08:00:00 GMT

Roche joins obesity drug chase with $2.7B deal for startup Carmot - BioPharma Dive

Sun, 03 Dec 2023 08:00:00 GMT

Roche to buy Carmot for up to $3.1bn as race for obesity drugs intensifies - Financial Times

Fri, 26 Jul 2024 07:00:00 GMT

Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy - BioSpace

Live intelligence

Get deeper insights on Carmot Therapeutics Inc.

✓

Direct contacts for 5 executives

✓

AI alerts when similar companies raise funding

✓

Track Carmot Therapeutics Inc.'s next moves

Used by teams at Oracle, Google, LinkedIn

Related people

Trends

	Raised	Growth The data in the raised column shows reported funding for this location/industry over last 90 days. The data in the growth column indicates the % increase or decrease of the last 90 days vs. the previous 90 days. Please note: one or more large fundings, especially for a location/industry that doesn't historically receive much funding, can have a significant impact on the increase or decrease percentage.
berkeley	$260.5 M	-59.3%
biotechnology	$8.5 B	-25.5%